SINGAPORE (Feb 8): Trendlines Medical Singapore, a subsidiary of Israeli company The Trendlines Group, is partnering Singapore-based investor Ozi Amanat’s venture capital firm, K2 Global, to collaborate in SPRING SEEDS Capital’s (SSC) $100 million investment allocation via the Startup SG Equity scheme.

Under the Startup SG Equity scheme, SSC supports early-stage startups across the technology and industry domain areas, and catalyses private-sector investments for startups via government equity co-investment.

The scheme announced its $100 million investment allocation in July 2017 to groom start-ups, and issued a call to its appointed partners to co-invest in the health & biomedical sciences and other fields.

In a Thursday announcement, Trendlines says it intends to invest in medical technology companies seeking Series A funding through its partnership with K2 Global. Both companies anticipate co-investing with SCC in more than 11 companies over the agreed partnership period of eight years.

They also consider the pipeline of deals originating from Trendlines Medical Singapore’s incubator, along with other companies that have strong development focus in Singapore, as “a rich environment for investment”.

Eric Loh, CEO of Trendlines Medical Singapore, sees the collaboration as one that leverages Trendlines’ experience and track record in identifying, incubating and grooming medical technology companies, while working closely with K2 Global to provide growth capital and support to help scale operations and facilitate global opportunities.

“This is an ideal relationship that will contribute substantial value to Singapore’s medical technology start-up ecosystem,” says Loh.

“Our participation in the Startup SG Equity program broadens our ability to develop early-stage medical technology companies in Singapore. Our collaboration with K2 Global will further strengthen our successful efforts in raising funds from strategic investors to boost the value of our portfolio companies. We expect numerous successful investment outcomes in the coming years,” adds Todd Dollinger, chairman of Trendlines Medical Singapore.

Shares in Trendlines close flat at 14 cents on Thursday.